Overview

An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies

Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
An open-label study for participants who are non-responders at end of the treatment period assessment (i.e., 15 weeks) in the VRND-001-101 (THRIVE) and VRDN-001-301 (THRIVE-2) pivotal studies
Phase:
Phase 3
Details
Lead Sponsor:
Viridian Therapeutics, Inc.